Pervasis Tackling PAD with $17M Round

September 2009
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p4
The article reports on the new venture entered by Pervasis Therapeutics Inc. for the Phase II of its studies on peripheral arterial disease (PAD) in Cambridge, Massachusetts. It states that Pervasis has padded its bank account to seek partners for its Vascugel program and for the special protocol assessment it submitted. It adds that the scheme will help in the development of the endothelial technology designed for PAD.


Related Articles

  • Pervasis Tackling PAD with $17M Round; Seeks Vascugel Partner. Boggs, Jennifer // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p1 

    The article reports on the move by Cambridge, Massachusetts-based Pervasis Therapeutics Inc. to secure a 17 million dollars in venture funding to finance work on a second-level development candidate for its endothelial technology. It explains that the company is also seeking a partner for its...

  • Pervasis Gets $9.75M for Blood Vessel Product.  // Bioworld Week;1/21/2008, Vol. 16 Issue 3, p4 

    The article reports that Pervasis Therapeutics Inc. in Cambridge, Massachusetts raised $9.75 million to support the Phase II development of its Vascugel blood vessel repair product and to conduct research on expanding the product's uses. The company completed patient enrollment for its two Phase...

  • Product pipeline.  // Cardiovascular Device Update;Oct2007, Vol. 13 Issue 10, p35 

    The article reports on the publication of animal data for Cambridge, Massachusetts-based Pervasis Therapeutics' Vascugel product under investigation to aid in healing, function, and remodeling of traumatized veins and arteries. The product is a biologically active matrix of endothelial cells...

  • Pervasis Therapeutics. M. T. // Red Herring;10/7/2007, Vol. 4 Issue 29, p73 

    The article features Pervasis Therapeutics, a biosciences company included in "Red Herring's" top 100 list for 2007. The company is based in Cambridge, Massachusetts. It was founded in 2003. Its chief executive officer (CEO) is Stephen Bollinger. Among its key investors are Flagship Venture...

  • Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections. Nichols, Wilmer W.; Epstein, Benjamin J. // Current Pharmaceutical Design;1/21/2009, Vol. 15 Issue 3, p304 

    The large conduit arteries of the thorax and abdomen are elastic while those in the arms and legs are muscular. Alterations in wall properties of elastic arteries occur over time and are usually permanent in nature; acute changes can, however, occur is response to a change in transmural...

  • Key Global Literature. Fonseca, Vivian // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2571 

    Presents an abstract of the article "Endothelial Dysfunction and Increased Arterial Intima-Media Thickness in Children With Type 1 Diabetes," by M. J. Jarvisalo, M. Raitakari, J. O. Toikka, A. Putto-Laurila, R. Rontu, S. Laine, T. Lehtimaki, T. Ronnemaa, J. Viikari and O. T. Raitakari.

  • CLINIC ROUNDUP.  // BioWorld Today;8/14/2007, Vol. 18 Issue 157, p2 

    This section offers news briefs related to biotechnology companies. The U.S. FDA approved the clinical development of AV411 by Avigen Inc. Oragenics Inc. announced that the FDA placed a clinical hold on a proposed safety study of its SMaRT Replacement Therapy. Pervasis Therapeutics Inc. has...

  • Pervasis Gets $9.75M to Boost Blood Vessel Repair Candidate.  // BioWorld Today;1/16/2008, Vol. 19 Issue 11, p2 

    This article reports on the succesful financing deal completed by Pervasis Therapeutics Inc. to support the development of its Vascugel blood vessel repair product and to conduct research on the product's expanding applications. A total of $9.75 million was raised by Pervasis. Some of the...

  • Pervasis, FDA Agree on Phase III as Partner Talks Advance. Hollingsworth, Catherine // BioWorld Today;2/2/2010, Vol. 21 Issue 21, p2 

    The article focuses on an agreement reached by Pervasis Therapeutics Inc. with the U.S. Food and Drug Administration (FDA) on the design of a single, Phase III study of Vascugel. The investigational new drug is aimed at preventing the failure of arteriovenous grafts in dialysis patients....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics